Results 161 to 170 of about 73,583 (263)

Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain

Alimentary Pharmacology &Therapeutics, EarlyView.
Clinical burden of symptomatic HEV‐3 infection in southern Spain. Between 2022 and 2025, 1124 patients with acute hepatitis, defined as ALT ≥ 3 times the upper limit of normal and negative screening for HAV, HBV, HCV, EBV and CMV, were evaluated in Andalusia.
María Casares‐Jimenez, Claudia Ferreira‐Tata, Isabel Viciana, Carolina Freyre‐Carrillo, Pedro Lopez‐Lopez, Ana Belen Perez, Berta Becerril‐Carral, Ana Fuentes, Juan Macías, Lucia Rios‐Muñoz, Francisco Franco‐Alvarez de Luna, María Teresa Cabezas‐Fernandez, Diana Corona‐Mata, Antonio Rivero‐Juarez, Antonio Rivero   +14 more
wiley   +1 more source

Low 25(OH)Vitamin D levels are associated with nutritional risk and disease severity in outpatient individuals with advanced chronic liver disease. [PDF]

J Nutr Sci
Albuquerque JMDC, Rodrigues Junior JI, Siqueira AIAN, Santos JCF, de Barros-Neto JA, Bueno NB, Moura FA.   +6 more
europepmc   +1 more source

Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial

Alimentary Pharmacology &Therapeutics, EarlyView.
RESTORE is a prospective, double‐blind, placebo‐controlled, crossover trial evaluating Lemborexant in cirrhosis at Cipto Mangunkusumo National Referral Hospital. Both 5 and 10 mg doses reduced PSQI by week 2, with sustained benefits post‐crossover. The 5 mg group improved Stroop Test performance, whereas the 10 mg group had prolonged reaction time ...
Rino Alvani Gani, Pitt Akbar, Irsan Hasan, Andri Sanityoso Sulaiman, Cosmas Rinaldi Adithya Lesmana, Juferdy Kurniawan, Sarah Melissa Panjaitan, Valerie Josephine Dirjayanto   +7 more
wiley   +1 more source

THE DOUBLE BURDEN OF CIRRHOSIS AND ACUTE PANCREATITIS: AMPLIFIED RISKS FOR NUTRITIONAL AND GASTROINTESTINAL COMPLICATIONS. [PDF]

Arq Gastroenterol
Onwuzo CN, Odunsanya KE, Alvina F, Razeq RA, Awuah KB, Onwuzo S.   +5 more
europepmc   +1 more source

Meta‐Analysis: Redefining Liver Disease Risk in Heterozygous Alpha‐1 Antitrypsin Deficiency

Alimentary Pharmacology &Therapeutics, EarlyView.
SERPINA1 MZ/SZ genotypes is a common but under‐recognised liver risk state. Despite modest shifts in liver function tests, it is associated with approximately doubled odds of fibrosis, cirrhosis, and liver transplantation, supporting its inclusion in chronic liver disease risk assessment.
Adam M. Syanda, Dimitra Georgantaki, Riona T. T. Linn, Amara Agbai, Hassan Tahir, Manako Sakai, Richard Thompson, Mariam Molokhia, S. Tamir Rashid   +8 more
wiley   +1 more source

Alcohol Abstinence Is Associated with Regression of Non-Invasive Fibrosis Markers in Patients with Metabolic Syndrome: A 12-Month Prospective Study. [PDF]

J Clin Med
Mihăilă D, Domnariu HP, Moga DF, Domnariu CD.   +3 more
europepmc   +1 more source

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection

Alimentary Pharmacology &Therapeutics, EarlyView.
Cirrhosis patients with untreated HBV in Ethiopia exhibit a distinct immune profile marked by depletion of NK cells, B cells, and T cells, alongside an expanded CD38+HLA‐DR+ CD8 T‐cell population. ABSTRACT Background and Aims The immune cell phenotype of African patients living with chronic hepatitis B virus (HBV) infection is rarely described, despite
Julia MacLeod, Fikadu G. Gudissa, Asiya Jeylan, Nega Berhe, Hailemichael Desalegn, Lasse Rossvoll, Asgeir Johannessen, Niklas K. Björkström, Dag Henrik Reikvam, Annika Niehrs   +9 more
wiley   +1 more source

Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies. [PDF]

Front Endocrinol (Lausanne)
Tang M, Ma Y, Wang Y.
europepmc   +1 more source

Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension

Alimentary Pharmacology &Therapeutics, EarlyView.
In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Christopher L. Bowlus, Frederik Nevens, Kris V. Kowdley, Alan Bonder, Thomas Capozza, Jing Li, Radhika Nair, Michael Trauner, David E. Jones   +8 more
wiley   +1 more source